Per conubia nostra, per inceptos hime Mauris in erat justom etone. Per conub per inceptos hime naeos.
Our London Shop
9235 Bayberry Drive
Hendersonville, NC 28792
london@email.com
+51853 458 243
Jalon Therapeutics raised a pre-Seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. Its growth ambition
is to raise a Seed immediately followed by a Series A to finance up to
the clinical proof of concept of its lead candidate JRT39.
As Jalon Therapeutics further develops its scientific platform and its lead drug candidate JRT39 up to clinical stage, we seek bright and motivated professionals, industrial partners and investors,
to maximize the value of our proprietary assets.
JALON THERAPEUTICS RAISES NEARLY 2 MILLION EUROS TO DEVELOP A DISRUPTIVE APPROACH IN ONCOLOGY
“We are proud to have raised these funds, which allow us to pursue our preclinical characterization studies,” commented Jérôme Tiollier, Executive Chairman and co-founder of Jalon Therapeutics, and David Loison, CEO.
The company now aims to raise the capital needed to finance the regulatory studies prior to future phase I/II clinical trials as well as proof of clinical concept.
contact [at] jalontx.com
27 rue Juliette Dodu
75010 Paris, France
Sign up here to get the latest news and updates delivered to your inbox.
Per conubia nostra, per inceptos hime Mauris in erat justom etone. Per conub per inceptos hime naeos.
9235 Bayberry Drive
Hendersonville, NC 28792
london@email.com
+51853 458 243